{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-009697","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.243183+00:00","generated_at":"2026-06-04T05:42:58.230150+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CervoMed secures $50M upfront private placement; warrants could add $99.4M; funds Phase 2b DLB trial","bullets":["Gross proceeds ~$50M upfront; up to ~$149.4M if Series A warrants ($39.24/share, 100% premium) fully exercised.","Unit price $19.745; includes pre-funded warrants ($0.001 strike) and Series A warrants expiring Apr 2027 or post positive Phase 2b data.","Financing led by RA Capital Management with Armistice, Special Situations, Soleus; Morgan Stanley and Canaccord placement agents.","Net proceeds to fund neflamapimod R&D for dementia with Lewy bodies; expected cash runway through end of 2025.","Closing expected April 1, 2024; resale registration statement to be filed within 60 days after close."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-009697","json":"https://secwatch.observer/filing/0001437749-24-009697.json","markdown":"https://secwatch.observer/filing/0001437749-24-009697.md","text":"https://secwatch.observer/filing/0001437749-24-009697.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924009697/0001437749-24-009697-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924009697/crvo20240326_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:42:58.230150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d64f9530b1bee6087636f23a9894e0e308114086","claim":"CervoMed Inc. entered into Purchase Agreement with purchasers named therein valued at approximately $50 million (effective 2024-03-28).","evidence_excerpt":"On March 28, 2024, CervoMed Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of an aggregate of 2,532,285 units","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924009697/0001437749-24-009697-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"purchasers named therein"},{"label":"Value","value":"approximately $50 million"},{"label":"Effective","value":"2024-03-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}